156 related articles for article (PubMed ID: 36531550)
1. Expression of Neuron-Specific Enolase and Other Neuroendocrine Markers is Correlated with Prognosis and Response to Therapy in Non-Hodgkin Lymphoma.
Chowdhury S; Kataria SP; Yadav AK
J Lab Physicians; 2022 Dec; 14(4):427-434. PubMed ID: 36531550
[No Abstract] [Full Text] [Related]
2. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
3. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
[TBL] [Abstract][Full Text] [Related]
4. Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation.
Mjønes P; Sagatun L; Nordrum IS; Waldum HL
J Histochem Cytochem; 2017 Dec; 65(12):687-703. PubMed ID: 28972818
[TBL] [Abstract][Full Text] [Related]
5. Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer.
O'Shea P; Cassidy M; Freaney R; McCarthy P; Fennelly J
Ir J Med Sci; 1995 Jan; 164(1):31-6. PubMed ID: 7890531
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL).
Nakatsuka S; Nishiu M; Tomita Y; Miwa H; Takakuwa T; Iuchi K; Yamamoto S; Aozasa K
Jpn J Cancer Res; 2002 Apr; 93(4):411-6. PubMed ID: 11985791
[TBL] [Abstract][Full Text] [Related]
8. Aberrant synaptophysin expression in classic Hodgkin lymphoma.
Im S; Kim JA; Park G; Cho U
Diagn Pathol; 2022 Nov; 17(1):90. PubMed ID: 36401284
[TBL] [Abstract][Full Text] [Related]
9. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
10. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
11. Expression of pan-neuroendocrine proteins in 53 neuroblastic tumors. An immunohistochemical study with neuron-specific enolase, chromogranin, and synaptophysin.
Hachitanda Y; Tsuneyoshi M; Enjoji M
Arch Pathol Lab Med; 1989 Apr; 113(4):381-4. PubMed ID: 2495784
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
14. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Wang J; Young L; Win W; Taylor CR
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):323-32. PubMed ID: 16280661
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study.
Slodkowska J; Zych J; Szturmowicz M; Demkow U; Rowinska-Zakrzewska E; Roszkowski-Sliz K
Int J Biol Markers; 2005; 20(4):217-26. PubMed ID: 16398403
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M; Saeki H; Kuwano H; Miyazaki T; Yokobori T; Sano A; Sakai M; Kakeji Y; Toh Y; Doki Y; Matsubara H
Ann Surg Oncol; 2021 Nov; 28(12):7983-7989. PubMed ID: 33843025
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase.
Simpson S; Vinik AI; Marangos PJ; Lloyd RV
Cancer; 1984 Oct; 54(7):1364-9. PubMed ID: 6088026
[TBL] [Abstract][Full Text] [Related]
18. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]